Do analysts recommend CCM or BGLC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Concord Medical Services 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioNexus Gene Lab 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, CCM or BGLC?

BioNexus Gene Lab has lower revenue, but higher earnings than Concord Medical Services. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Concord Medical Services $65.85M 0.30 -$13.27M N/A N/A BioNexus Gene Lab $7.43M 0.79 -$2.98M -$1.48 N/A

Do analysts recommend MRAI or BGLC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 BioNexus Gene Lab 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MRAI or BGLC more profitable?

BioNexus Gene Lab has a net margin of -54.70% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat BioNexus Gene Lab's return on equity. Company Net Margins Return on Equity Return on Assets Marpai -85.70% N/A -100.23% BioNexus Gene Lab -54.70% -37.43% -32.88%

Do analysts recommend BMGL or BGLC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioNexus Gene Lab 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, BMGL or BGLC?

BioNexus Gene Lab has lower revenue, but higher earnings than Basel Medical Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Basel Medical Group $8.90M 1.21 -$9.50M N/A N/A BioNexus Gene Lab $7.43M 0.79 -$2.98M -$1.48 N/A

Do analysts prefer BGLC or BRTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioNexus Gene Lab 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate BGLC or ADVB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioNexus Gene Lab 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Advanced Biomed 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

BioNexus Gene Lab (BGLC) Competitors

$2.42 0.00 (0.00%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$2.32 -0.10 (-4.30%)

As of 06:39 AM Eastern

Compare

BGLC vs. CCM, MRAI, BMGL, BRTX, and ADVB

Should you buy BioNexus Gene Lab stock or one of its competitors? MarketBeat compares BioNexus Gene Lab with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioNexus Gene Lab include Concord Medical Services (CCM), Marpai (MRAI), Basel Medical Group (BMGL), Biorestorative Therapies (BRTX), and Advanced Biomed (ADVB). These companies are all part of the "healthcare" industry.

How does BioNexus Gene Lab compare to Concord Medical Services?

Concord Medical Services (NYSE:CCM) and BioNexus Gene Lab (NASDAQ:BGLC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Concord Medical Services has a beta of -0.99, suggesting that its stock price is 199% less volatile than the broader market. Comparatively, BioNexus Gene Lab has a beta of 4.06, suggesting that its stock price is 306% more volatile than the broader market.

Concord Medical Services has a net margin of 0.00% compared to BioNexus Gene Lab's net margin of -54.70%. Concord Medical Services' return on equity of 0.00% beat BioNexus Gene Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Concord Medical Services	N/A	N/A	N/A
BioNexus Gene Lab	-54.70%	-37.43%	-32.88%

18.9% of BioNexus Gene Lab shares are owned by institutional investors. 46.5% of Concord Medical Services shares are owned by company insiders. Comparatively, 0.1% of BioNexus Gene Lab shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

BioNexus Gene Lab has lower revenue, but higher earnings than Concord Medical Services.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Concord Medical Services	$65.85M	0.30	-$13.27M	N/A	N/A
BioNexus Gene Lab	$7.43M	0.79	-$2.98M	-$1.48	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Concord Medical Services	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioNexus Gene Lab	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Concord Medical Services' average media sentiment score of 0.00 equaled BioNexus Gene Lab'saverage media sentiment score.

Company	Overall Sentiment
Concord Medical Services	Neutral
BioNexus Gene Lab	Neutral

Summary

Concord Medical Services beats BioNexus Gene Lab on 5 of the 9 factors compared between the two stocks.

How does BioNexus Gene Lab compare to Marpai?

Marpai (NASDAQ:MRAI) and BioNexus Gene Lab (NASDAQ:BGLC) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Marpai has a beta of 4.94, suggesting that its share price is 394% more volatile than the broader market. Comparatively, BioNexus Gene Lab has a beta of 4.06, suggesting that its share price is 306% more volatile than the broader market.

BioNexus Gene Lab has lower revenue, but higher earnings than Marpai. BioNexus Gene Lab is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marpai	$34.87M	0.49	-$28.75M	-$0.87	N/A
BioNexus Gene Lab	$7.43M	0.79	-$2.98M	-$1.48	N/A

49.8% of Marpai shares are owned by institutional investors. Comparatively, 18.9% of BioNexus Gene Lab shares are owned by institutional investors. 46.1% of Marpai shares are owned by insiders. Comparatively, 0.1% of BioNexus Gene Lab shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Marpai had 1 more articles in the media than BioNexus Gene Lab. MarketBeat recorded 1 mentions for Marpai and 0 mentions for BioNexus Gene Lab. Marpai's average media sentiment score of 0.00 equaled BioNexus Gene Lab'saverage media sentiment score.

Company	Overall Sentiment
Marpai	Neutral
BioNexus Gene Lab	Neutral

BioNexus Gene Lab has a net margin of -54.70% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat BioNexus Gene Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marpai	-85.70%	N/A	-100.23%
BioNexus Gene Lab	-54.70%	-37.43%	-32.88%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
BioNexus Gene Lab	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Marpai beats BioNexus Gene Lab on 8 of the 13 factors compared between the two stocks.

How does BioNexus Gene Lab compare to Basel Medical Group?

Basel Medical Group (NASDAQ:BMGL) and BioNexus Gene Lab (NASDAQ:BGLC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioNexus Gene Lab	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Basel Medical Group had 1 more articles in the media than BioNexus Gene Lab. MarketBeat recorded 1 mentions for Basel Medical Group and 0 mentions for BioNexus Gene Lab. Basel Medical Group's average media sentiment score of 0.00 equaled BioNexus Gene Lab'saverage media sentiment score.

Company	Overall Sentiment
Basel Medical Group	Neutral
BioNexus Gene Lab	Neutral

Basel Medical Group has a net margin of 0.00% compared to BioNexus Gene Lab's net margin of -54.70%. Basel Medical Group's return on equity of 0.00% beat BioNexus Gene Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Basel Medical Group	N/A	N/A	N/A
BioNexus Gene Lab	-54.70%	-37.43%	-32.88%

Basel Medical Group has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market. Comparatively, BioNexus Gene Lab has a beta of 4.06, meaning that its stock price is 306% more volatile than the broader market.

BioNexus Gene Lab has lower revenue, but higher earnings than Basel Medical Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Basel Medical Group	$8.90M	1.21	-$9.50M	N/A	N/A
BioNexus Gene Lab	$7.43M	0.79	-$2.98M	-$1.48	N/A

18.9% of BioNexus Gene Lab shares are owned by institutional investors. 0.1% of BioNexus Gene Lab shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Basel Medical Group beats BioNexus Gene Lab on 6 of the 10 factors compared between the two stocks.

How does BioNexus Gene Lab compare to Biorestorative Therapies?

BioNexus Gene Lab (NASDAQ:BGLC) and Biorestorative Therapies (NASDAQ:BRTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

BioNexus Gene Lab has a net margin of -54.70% compared to Biorestorative Therapies' net margin of -3,088.27%. BioNexus Gene Lab's return on equity of -37.43% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNexus Gene Lab	-54.70%	-37.43%	-32.88%
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNexus Gene Lab	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BioNexus Gene Lab has higher revenue and earnings than Biorestorative Therapies. BioNexus Gene Lab is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNexus Gene Lab	$7.43M	0.79	-$2.98M	-$1.48	N/A
Biorestorative Therapies	$360K	27.54	-$14.24M	-$1.07	N/A

18.9% of BioNexus Gene Lab shares are owned by institutional investors. Comparatively, 69.4% of Biorestorative Therapies shares are owned by institutional investors. 0.1% of BioNexus Gene Lab shares are owned by insiders. Comparatively, 13.6% of Biorestorative Therapies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

BioNexus Gene Lab has a beta of 4.06, suggesting that its share price is 306% more volatile than the broader market. Comparatively, Biorestorative Therapies has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market.

In the previous week, Biorestorative Therapies had 1 more articles in the media than BioNexus Gene Lab. MarketBeat recorded 1 mentions for Biorestorative Therapies and 0 mentions for BioNexus Gene Lab. BioNexus Gene Lab's average media sentiment score of 0.00 equaled Biorestorative Therapies'average media sentiment score.

Company	Overall Sentiment
BioNexus Gene Lab	Neutral
Biorestorative Therapies	Neutral

Summary

BioNexus Gene Lab and Biorestorative Therapies tied by winning 6 of the 12 factors compared between the two stocks.

How does BioNexus Gene Lab compare to Advanced Biomed?

BioNexus Gene Lab (NASDAQ:BGLC) and Advanced Biomed (NASDAQ:ADVB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNexus Gene Lab	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Advanced Biomed	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BioNexus Gene Lab has higher revenue and earnings than Advanced Biomed. BioNexus Gene Lab is trading at a lower price-to-earnings ratio than Advanced Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNexus Gene Lab	$7.43M	0.79	-$2.98M	-$1.48	N/A
Advanced Biomed	N/A	N/A	-$3.26M	$4.82	1.06

Advanced Biomed has a net margin of 0.00% compared to BioNexus Gene Lab's net margin of -54.70%. Advanced Biomed's return on equity of 87.74% beat BioNexus Gene Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNexus Gene Lab	-54.70%	-37.43%	-32.88%
Advanced Biomed	N/A	87.74%	64.49%

BioNexus Gene Lab has a beta of 4.06, indicating that its share price is 306% more volatile than the broader market. Comparatively, Advanced Biomed has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market.

In the previous week, BioNexus Gene Lab's average media sentiment score of 0.00 equaled Advanced Biomed'saverage media sentiment score.

Company	Overall Sentiment
BioNexus Gene Lab	Neutral
Advanced Biomed	Neutral

18.9% of BioNexus Gene Lab shares are owned by institutional investors. 0.1% of BioNexus Gene Lab shares are owned by company insiders. Comparatively, 27.0% of Advanced Biomed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Advanced Biomed beats BioNexus Gene Lab on 6 of the 10 factors compared between the two stocks.

Get BioNexus Gene Lab News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BGLC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BGLC vs. The Competition

Export

Metric	BioNexus Gene Lab	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.85M	$8.69B	$6.45B	$12.38B
Dividend Yield	N/A	1.73%	2.69%	5.83%
P/E Ratio	-1.64	23.42	24.66	23.99
Price / Sales	0.79	18.08	526.33	107.23
Price / Cash	N/A	98.97	44.82	54.51
Price / Book	0.68	5.71	10.72	6.50
Net Income	-$2.98M	$174.80M	$3.56B	$336.88M
7 Day Performance	-3.97%	0.15%	0.94%	-0.16%
1 Month Performance	20.10%	1.54%	0.36%	0.76%
1 Year Performance	-9.36%	8.61%	29.67%	28.49%

BioNexus Gene Lab Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BGLC BioNexus Gene Lab	0.3333 of 5 stars	$2.42 flat	N/A	-11.7%	$5.85M	$7.43M	N/A	30	Gap Up
CCM Concord Medical Services	0.4416 of 5 stars	$5.42 +15.3%	N/A	-21.4%	$20.41M	$65.85M	N/A	970	High Trading Volume
MRAI Marpai	N/A	$0.62 -4.8%	N/A	-49.1%	$15.85M	$34.87M	N/A	150	Gap Down
BMGL Basel Medical Group	0.7139 of 5 stars	$0.59 -5.7%	N/A	-76.0%	$11.84M	$8.90M	N/A	36	Gap Down
BRTX Biorestorative Therapies	0.4242 of 5 stars	$0.40 +13.1%	N/A	-76.3%	$9M	$360K	N/A	7

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BGLC) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioNexus Gene Lab (BGLC) Competitors

BGLC vs. CCM, MRAI, BMGL, BRTX, and ADVB

How does BioNexus Gene Lab compare to Concord Medical Services?

Summary

How does BioNexus Gene Lab compare to Marpai?

Summary

How does BioNexus Gene Lab compare to Basel Medical Group?

Summary

How does BioNexus Gene Lab compare to Biorestorative Therapies?

Summary

How does BioNexus Gene Lab compare to Advanced Biomed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGLC vs. The Competition

BioNexus Gene Lab Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioNexus Gene Lab (BGLC) Competitors

BGLC vs. CCM, MRAI, BMGL, BRTX, and ADVB

How does BioNexus Gene Lab compare to Concord Medical Services?

Which has more volatility & risk, CCM or BGLC?

Is CCM or BGLC more profitable?

Do institutionals and insiders believe in CCM or BGLC?

Which has better valuation and earnings, CCM or BGLC?

Do analysts recommend CCM or BGLC?

Does the media prefer CCM or BGLC?

Summary

How does BioNexus Gene Lab compare to Marpai?

Which has more risk and volatility, MRAI or BGLC?

Which has higher earnings & valuation, MRAI or BGLC?

Do institutionals & insiders believe in MRAI or BGLC?

Does the media prefer MRAI or BGLC?

Is MRAI or BGLC more profitable?

Do analysts recommend MRAI or BGLC?

Summary

How does BioNexus Gene Lab compare to Basel Medical Group?

Do analysts recommend BMGL or BGLC?

Does the media refer more to BMGL or BGLC?

Is BMGL or BGLC more profitable?

Which has more volatility and risk, BMGL or BGLC?

Which has better earnings and valuation, BMGL or BGLC?

Do insiders & institutionals have more ownership in BMGL or BGLC?

Summary

How does BioNexus Gene Lab compare to Biorestorative Therapies?

Is BGLC or BRTX more profitable?

Do analysts prefer BGLC or BRTX?

Which has stronger earnings & valuation, BGLC or BRTX?

Do institutionals and insiders have more ownership in BGLC or BRTX?

Which has more risk & volatility, BGLC or BRTX?

Does the media favor BGLC or BRTX?

Summary

How does BioNexus Gene Lab compare to Advanced Biomed?

Do analysts rate BGLC or ADVB?

Which has better earnings & valuation, BGLC or ADVB?

Is BGLC or ADVB more profitable?

Which has more risk & volatility, BGLC or ADVB?

Does the media refer more to BGLC or ADVB?

Do insiders and institutionals hold more shares of BGLC or ADVB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGLC vs. The Competition

BioNexus Gene Lab Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools